Sadly, in July 2025, the California Institute for Regenerative Medicine (CIRM) officially closed its iPSC Repository, marking the end of one of the world’s most comprehensive publicly funded collections of human induced pluripotent stem cell (hiPSC) lines. With the repository’s closure, these cells are no longer available for purchase or distribution, a development that has drawn wide attention and sadness across the global stem cell community. [Read more…]
Qkine launches cell therapy grade recombinant proteins to support next-generation therapies
1st October 2025, Cambridge, UK – Qkine, Ltd., a specialist bioactive protein manufacturer with its core technology developed at the University of Cambridge, today announced the launch of its Cell Therapy Grade proteins, engineered to support the stringent requirements of cell therapy research, process development, and GMP manufacturing. [Read more…]
TEDCO Announces Panel to Discuss the Road to Clinical Trials at 2025 Entrepreneur Expo
COLUMBIA, Md., October 9, 2025 — TEDCO, Maryland’s economic engine for technology companies, announces the panel “The Road to Clinical Trials” to take place at the upcoming 2025 Entrepreneur Expo at The Hotel at the University of Maryland on October 21, 2025.
“The transition from discovery to clinical application represents one of the most complex and pivotal phases of medical research” said Ben Antebi, associate director, Maryland Stem Cell Research Fund (MSCRF). “Navigating this critical pathway properly has a direct impact on shaping the fate of a technology.” [Read more…]
Xintela’s stem cell product XSTEM shows safety and sustained positive efficacy results two years after treatment in knee osteoarthritis clinical study
The final analysis including the 24-month evaluation of Xintela’s (XINT) clinical study on XSTEM for knee osteoarthritis has now been completed. The results show continued safety, reduction of knee pain, improved joint function, and improvements in bone and cartilage structure. This confirms a sustained treatment effect in knee osteoarthritis and supports a disease-modifying effect of XSTEM. Xintela has previously communicated positive interim results up to 18 months after treatment of knee osteoarthritis patients with three dose levels of XSTEM. The highest dose level, which showed the best results after 18 months, has now shown sustained positive treatment effects two years after XSTEM treatment.
XSTEM, which consists of allogeneic (donated) integrin α10β1-selected mesenchymal stem cells, is developed and manufactured by Xintela. [Read more…]
Maryland Governor Wes Moore to Speak at TEDCO’s 2025 Entrepreneur Expo
Join us in College Park on October 21 during the lunch keynote session
COLUMBIA, Md., Sept. 29, 2025 — TEDCO, Maryland’s economic engine for technology companies, announces the attendance of Maryland Governor Wes Moore at the upcoming 2025 Entrepreneur Expo. The premier event will take place at The Hotel at the University of Maryland on October 21, 2025. Gov. Moore will be making a special appearance during the lunch keynote session. [Read more…]
- « Previous Page
- 1
- …
- 34
- 35
- 36
- 37
- 38
- …
- 334
- Next Page »